Cancer Research · 2012 · 47 citations · 0 references
MedicineOncologyPharmacologyBreast OncologyChemotherapyMolecular OncologyAdjuvant ChemotherapyAdjuvant PharmacotherapyAdjuvant TherapyBreast Cancer OncologyCancer ImmunotherapyHer2-positive Breast CancerAdjuvant Her2-directed TherapyBreast Cancer ChemotherapyDisease-free Survival AnalysisDisease-free Survival AssessmentHer2-positive Breast Cancer ImmunotherapyHer2-positive Breast Cancer TherapyHuman Epidermal Growth Factor Receptor 2-Targeted TherapySurgical Adjuvant Therapy
Abstract Background: Preplanned combined analysis of the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-31 trial and North Central Cancer Treatment Group (NCCTG) (Alliance) N9831 Trial compared adjuvant chemotherapy with or without trastuzumab in women with HER2-positive breast cancer. The initial results were reported in 2005 and updated in early 2011 Methods: 4045 patients with HER2-positive operable breast cancer were enrolled to receive doxorubicin plus cyclophosphamide followed by paclitaxel with or without trastuzumab in both trials. The definitive analysis for OS will occur when 710 events have been reported. Results: Median time on study is 8 years. The required number of events have occurred for the definitive analysis for OS to be conducted by the end of September 2012. Updated analyses of disease free survival and related subgroups will also be presented. Supported by NCI grants U10-CA-12027, -69651, -37377, -69974, -44066, U24-CA-114732, CA25224; Breast Cancer Research Foundation; Genentech 35–03 Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr S5-5.